<DOC>
	<DOCNO>NCT00940251</DOCNO>
	<brief_summary>To determine safety efficacy Ayurvedic formulation , Mersina type 2 diabetic patient secondary failure oral hypoglycemic agent , randomize double blind , single centre , study 3 month duration carry .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Mersina , Ayurvedic Formulation : A Double Blind , Placebo Controlled Study Type 2 Diabetic Patients With Secondary Failure Oral Drugs</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Secondary failure Oral Hypoglycemic Agents diagnose patient HbA1c level &gt; 8.5 % even supplementation maximal dose combination sulphonylurea ( 15 mg glybenclamide 160 mg gliclazide 15 mg glipizide ) metformin 1500 mg/day . Patients ketosis , diabetes related complication , hepatic renal disease , pancreatitis , cardiac problem , uncontrolled hypertension , malnutrition severe immune deficiency</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Ayurvedic formulation</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>secondary failure oral hypoglycemic agent</keyword>
	<keyword>antidiabetic</keyword>
</DOC>